David S. Morris, MD, FACS, presented “Doublets and Triplets: Patient Selection” during the 34th International Prostate Cancer Update on February 13, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Morris, David S. “Doublets and Triplets: Patient Selection.” February 2024. Accessed Nov 2024. https://grandroundsinurology.com/doublets-and-triplets-patient-selection/
Doublets and Triplets: Patient Selection – Summary
David S. Morris, MD, FACS, explores the nuances of patient selection for doublet and triplet therapies in prostate cancer, providing an in-depth analysis of current strategies and emerging evidence. He begins by outlining the principles behind using doublet and triplet therapies, focusing on the rationale for combining multiple agents to enhance therapeutic efficacy and overcome resistance mechanisms.
Dr. Morris discusses the critical factors influencing patient selection. He examines the role of clinical and molecular biomarkers in guiding therapy choices, highlighting how these markers can predict response to treatment and help identify patients who are most likely to benefit from more intensive therapeutic regimens. By leveraging biomarkers, clinicians can tailor treatments to achieve the best possible outcomes while minimizing adverse effects.
He reviews key clinical trials that have investigated doublet and triplet therapies, providing a detailed analysis of their design, results, and implications for clinical practice. His analysis includes a discussion on how to balance the potential advantages of aggressive treatment with the need to manage toxicity and maintain patient quality of life.
Dr. Morris also addresses the practical aspects of implementing doublet and triplet therapies, including considerations related to dosing, administration, and monitoring. He emphasizes the importance of a multidisciplinary approach in managing patients receiving these complex regimens, involving collaboration among oncologists, urologists, and other healthcare professionals to optimize care.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
